Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic CancerTalia Golan, Hedy L. Kindler, Pascal Hammel et al.|New England Journal of Medicine|2019Cited by 2.2k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upGuillem Argilés, Dirk Arnold, Josep Tabernero et al.|Annals of Oncology|2020Cited by 1.3k
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the EsophagusManish A. Shah, Ken Kato, Mukul Gupta et al.|JAMA Oncology|2018Cited by 518
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic CancerHedy L. Kindler, Talia Golan, Pascal Hammel et al.|Journal of Clinical Oncology|2022Cited by 224
Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.Talia Golan, Hedy L. Kindler, Pascal Hammel et al.|Journal of Clinical Oncology|2021Cited by 78